<DOC>
	<DOCNO>NCT01539083</DOCNO>
	<brief_summary>The purpose study determine bortezomib added consolidation treatment thalidomide prednisolone lead improved response patient multiple myeloma undergone autologous stem cell transplant initial treatment bortezomib , cyclophosphamide , dexamethasone .</brief_summary>
	<brief_title>Velcade ( Bortezomib ) Consolidation After Transplant</brief_title>
	<detailed_description>This open-label ( patient know identity study treatment ) , randomize ( patient assign chance different treatment ) study bortezomib administer consolidation therapy ( therapy give remission achieve ) thalidomide prednisolone versus thalidomide prednisolone alone previously untreated patient multiple myeloma . Multiple myeloma cancer plasma cell , type white blood cell present bone marrow . Patients study receive initial therapy bortezomib , cyclophosphamide , dexamethasone ( refer VCD induction therapy ) undergo autologous stem cell transplant ( ASCT ) ( procedure patient receive infusion immature blood cell [ stem cell ] body replenish body 's supply healthy blood-forming cell ) randomization one two treatment : Treatment A ( thalidomide 12 month disease progression prednisolone alternate day continue indefinitely disease progression ) Treatment B ( bortezomib 32 week addition thalidomide 12 month disease progression prednisolone alternate day , continue indefinitely disease progression . Throughout study , patient 's response therapy assess accord protocol-defined efficacy evaluation implement define disease response criterion ( International Myeloma Working Group [ IMWG ] criterion ) . Safety evaluate throughout study . Follow progression-free survival ( PFS ) overall survival ( OS ) conduct time randomization 3 year post-randomization . Two interim analysis plan . The final analysis conduct patient complete 12-month consolidation treatment phase discontinue . The primary endpoint number percent patient complete response good partial response define IMWG criterion multiple myeloma examine interim final analysis approximately 12 month consolidation therapy . At completion study , updated analysis PFS OS perform .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion criterion : Previously diagnose multiple myeloma base international myeloma work group ( IMWG ) criteria.and meet following ; Serum Mprotein great equal ( &gt; = ) 1 gram per deciliter ( g/dL ) ( &gt; =10 gram per liter ) ; Urine Mprotein &gt; =200 milligram ( mg ) per 24 hour Serum Free Light chain ( FLC ) assay : Involved FLC Level &gt; =10 mg/dL ( &gt; =100 mg/L ) provide serum FLC ratio normal Meet pretreatment laboratory criterion specify study protocol within 21 day baseline ( Day 1 Cycle 1 , bortezomib administration induction ) . Have ECOG status 02 . Men woman must practice appropriate method birth control specify study protocol signing informed consent form though 12month visit/early termination visit . Exclusion criterion : Has previously receive treatment multiple myeloma ( include prior therapy radiation pulse dexamethasone ) specify study protocol . Has history malignancy within 5 year enrolment specify study protocol . Has major surgery specify study protocol within 30 day enrolment . Had myocardial infarction within 6 month enrolment New York Heart Association ( NYHA ) Class III IV heart failure ( clinically significant cardiac medical history specify study protocol ) . Has condition , opinion investigator , would make participation best interest ( eg , compromise wellbeing ) patient could prevent , limit , confound protocolspecified assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>VELCADE</keyword>
	<keyword>Consolidation therapy</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Prednisolone</keyword>
	<keyword>Autologous stem cell transplant ( ASCT )</keyword>
	<keyword>VELCADE , cyclophosphamide , dexamethasone ( VCD ) induction therapy</keyword>
</DOC>